Charles Schwab Investment Management Inc Aclaris Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 33,079 shares of ACRS stock, worth $79,058. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,079Holding current value
$79,058% of portfolio
0.0%Shares
25 transactions
Others Institutions Holding ACRS
# of Institutions
81Shares Held
49.2MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$34.1 Million21.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$11.2 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$8.06 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.01MShares$7.18 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$6.58 Million0.11% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $159M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...